Phase 3 Head and Neck Cancer Trial, Recruiting NCT03919552 Sponsor: Nanfang Hospital, Southern Medical University Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 3 Head and Neck Cancer Trial, Recruiting

NCT03919552
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been newly diagnosed with a specific type of nasopharyngeal cancer called "non-keratinizing" (confirmed by tissue biopsy, based on World Health Organization classification)
  • People whose cancer has been staged as locally advanced (T3-4 with any lymph node involvement, or any T stage with significant lymph node involvement), based on the 8th edition staging system
  • People whose cancer has not spread to distant parts of the body
  • People who are well enough to carry out normal daily activities (as measured by a standard performance scale called the Karnofsky scale, with a score above 70)
  • People whose blood counts are within an acceptable range — including white blood cell count, haemoglobin, and platelets
  • People whose liver function tests are within acceptable limits
  • People whose kidneys are functioning well enough (measured by how well the kidneys filter waste from the blood)
  • People who have been fully informed about the nature of the trial and have signed a written consent form

Who may not be able to join:

  • People whose cancer is the keratinizing squamous cell type or basaloid squamous cell type
  • People aged 65 or older, or under 18 years of age
  • People whose treatment is planned with palliative intent (aimed at comfort rather than cure)
  • People who have had a previous cancer, unless it was a fully treated non-melanoma skin cancer or early-stage cervical cancer
  • People who are pregnant or breastfeeding
  • People who have previously received radiotherapy (with an exception for certain skin cancers treated outside the area being studied)
  • People who have previously received chemotherapy or surgery related to the current cancer (diagnostic procedures are allowed)
  • People with serious ongoing health conditions that could pose unacceptable risks or affect participation — examples listed include unstable heart disease, kidney disease, chronic hepatitis, poorly controlled diabetes, or significant emotional or psychological difficulties

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jian Guan, Nanfang Hospital, Southern Medical University

Phone: +86-13632102247

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Nanfang Hospital, Southern Medical University
Registry
ClinicalTrials.gov
Start date
31 January 2018
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Failure-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov